Pomerantz LLP is investigating Pasqal Holding SA for potential securities fraud following the company's announcement that it would cease participation in a French quantum computing program. This news caused Pasqal's stock to fall 8.36% to $6.14 per share. The investigation focuses on whether Pasqal and its executives engaged in unlawful business practices. Investors affected are encouraged to contact Pomerantz LLP for potential class action involvement.
Pasqal Holding SA is the subject of an investigation by Pomerantz Law Firm. For readers following the Technology sector, here is Pluang's market snapshot as of Nov 04, 2026 05:21 WIB: out of 150 priced US Technology stocks, 97 rose and 52 fell. Notable movers include Bitdeer Technologies Group (BTDR) up 13.45% at USD 7.00 with 100% buy orders, Gartner Inc (IT) down 13.28% at USD 204.22, and Iris Energy Limited (IREN) up 12.58% at USD 24.79 but with 95% sell orders. The most notable figure is BTDR's 13.45% gain.
Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...
Pomerantz LLP is investigating claims against Yiren Digital Ltd. for possible securities fraud following the company's disclosure of a 34% revenue decline and a significant net loss in Q4 2025. The company also reported increased delinquency rates an...
Pomerantz LLP is investigating Syndax Pharmaceuticals following the company's announcement that its Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint. This news caused Syndax's stock to drop by 2.59% on...
Pomerantz LLP is investigating HCA Healthcare and its executives for potential securities fraud following the company's sharp reduction in its 2026 profit forecast. The profit guidance cut was due to an unfavorable change in payer mix, which negative...
Pomerantz LLP is investigating ClearPoint Neuro and its executives for possible securities fraud following the release of disappointing clinical trial data by its partner, uniQure. The data showed the Huntington's disease treatment did not meet key c...
